Metformin or a pharmaceutically acceptable salt thereof for use in a method for treating a glucose related disorder, said method comprising administering to a subject in need thereof a pharmaceutical composition comprising (a) metformin or a pharmaceutically acceptable salt thereof; (b) a compound of formula wherein Ring A is wherein R 1a is a halogen atom, a lower alkyl group, or a lower alkoxy group, and R 2a and R 3a are hydrogen atoms; and Ring B is wherein R 4a is a phenyl group optionally substituted by a substituent selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a lower alkoxy group, a carbamoyl group, or a mono- or di-lower alkylcarbamoyl group, and R 5a is a hydrogen atom; and Y is -CH 2 -; or a pharmaceutically acceptable salt thereof; (c) between 5% and 50% by weight of diluent selected from the list comprising lactose, microcrystalline cellulose, dicalcium phosphate and starch; (d) between 1% and 10% by weight of binder; and (e) between 1% and 10% by weight of disintegrant selected from the list comprising sodium starch glycolate, croscarmellose sodium and crospovidone; wherein the metformin or pharmaceutically acceptable salt thereof is in an amount in the range of from 500 mg to 2000 mg; and the compound of formula is in an amount of from 10 mg to 300 mg. (a) metformin or a pharmaceutically acceptable salt thereof; (b) a compound of formula wherein Ring A is wherein R 1a is a halogen atom, a lower alkyl group, or a lower alkoxy group, and R 2a and R 3a are hydrogen atoms; and Ring B is wherein R 4a is a phenyl group optionally substituted by a substituent selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a lower alkoxy group, a carbamoyl group, or a mono- or di-lower alkylcarbamoyl group, and R 5a is a hydrogen atom; and Y is -CH 2 -; or a pharmaceutically acceptable salt thereof; wherein Ring A is wherein R 1a is a halogen atom, a lower alkyl group, or a lower alkoxy group, and R 2a and R 3a are hydrogen atoms; and Ring B is wherein R 4a is a phenyl group optionally substituted by a substituent selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a mono- or di-lower alkylamino group, a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a lower alkoxy group, a carbamoyl group, or a mono- or di-lower alkylcarbamoyl group, and R 5a is a hydrogen atom; and Y is -CH 2 -; or a pharmaceutically acceptable salt thereof; (c) between 5% and 50% by weight of diluent selected from the list comprising lactose, microcrystalline cellulose, dicalcium phosphate and starch; (d) between 1% and 10% by weight of binder; and (e) between 1% and 10% by weight of disintegrant selected from the list comprising sodium starch glycolate, croscarmellose sodium and crospovidone; wherein the metformin or pharmaceutically acceptable salt thereof is in an amount in the range of from 500 mg to 2000 mg; and the compound of formula is in an amount of from 10 mg to 300 mg.